WO1999004026A3 - Vecteurs lentiviraux - Google Patents
Vecteurs lentiviraux Download PDFInfo
- Publication number
- WO1999004026A3 WO1999004026A3 PCT/US1998/014996 US9814996W WO9904026A3 WO 1999004026 A3 WO1999004026 A3 WO 1999004026A3 US 9814996 W US9814996 W US 9814996W WO 9904026 A3 WO9904026 A3 WO 9904026A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lentiviral
- lentiviral vectors
- ltr
- lentiviral vector
- rre
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002296319A CA2296319A1 (fr) | 1997-07-18 | 1998-07-20 | Vecteurs lentiviraux |
AU85762/98A AU8576298A (en) | 1997-07-18 | 1998-07-20 | Lentiviral vectors |
EP98936923A EP1003894A2 (fr) | 1997-07-18 | 1998-07-20 | Vecteurs lentiviraux |
JP2000503232A JP2001510053A (ja) | 1997-07-18 | 1998-07-20 | レンチウイルスベクター |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5306697P | 1997-07-18 | 1997-07-18 | |
US60/053,066 | 1997-07-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999004026A2 WO1999004026A2 (fr) | 1999-01-28 |
WO1999004026A3 true WO1999004026A3 (fr) | 1999-04-08 |
Family
ID=21981716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/014996 WO1999004026A2 (fr) | 1997-07-18 | 1998-07-20 | Vecteurs lentiviraux |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1003894A2 (fr) |
JP (1) | JP2001510053A (fr) |
AU (1) | AU8576298A (fr) |
CA (1) | CA2296319A1 (fr) |
WO (1) | WO1999004026A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107949424B (zh) * | 2015-03-20 | 2022-03-01 | 天普大学-联邦高等教育系统 | Tat诱导的基于crispr/核酸内切酶的基因编辑 |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6531123B1 (en) | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
WO2000000600A2 (fr) * | 1997-09-22 | 2000-01-06 | Chang Lung Ji | Vecteurs lentiviraux |
US7470426B1 (en) | 1997-10-09 | 2008-12-30 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
US7780962B2 (en) | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
JP2002508338A (ja) * | 1997-12-12 | 2002-03-19 | ナルディニ,ルイジ | レンチウィルスベクターの治療使用 |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
CA2318575A1 (fr) * | 1998-01-16 | 1999-07-22 | Chiron Corporation | Vecteurs de therapie genique du virus de l'immunodeficience feline |
US6492166B1 (en) | 1998-07-29 | 2002-12-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of constitutive transport elements for host range control |
EP1390046A4 (fr) | 1999-04-15 | 2005-04-20 | Wellstat Biologics Corp | Traitement de neoplasmes avec des virus |
CA2371216A1 (fr) * | 1999-04-23 | 2000-11-02 | Centre For Translational Research In Cancer | Pseudotype de vecteur retroviral destine a la therapie genique du cancer |
EP1849873B1 (fr) * | 1999-04-29 | 2011-10-12 | Gbp Ip, Llc | Procédé et supports de production de vecteurs de lentivirus recombinant sécurisé à fort dosage |
US6730297B1 (en) | 1999-05-28 | 2004-05-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
EP1183383B1 (fr) * | 1999-06-09 | 2006-10-18 | Cambridge University Technical Services Limited | Vecteurs a encapsidation deficiente bases sur le siv |
US8147822B1 (en) | 1999-09-17 | 2012-04-03 | Wellstat Biologics Corporation | Oncolytic virus |
US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
WO2001089580A1 (fr) * | 2000-05-22 | 2001-11-29 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Transduction systemique et cardiovasculaire associee a des vecteurs lentiviraux |
AU2001265190A1 (en) * | 2000-05-30 | 2001-12-11 | University Of Rochester | Siv derived lentiviral vector systems |
US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
US6712612B1 (en) | 2000-12-12 | 2004-03-30 | Genecure Llc | Safe and stable retroviral helper cell line and related compositions and methods |
ATE437221T1 (de) | 2001-05-14 | 2009-08-15 | Gbp Ip Llc | Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie |
ATE527347T1 (de) | 2001-08-02 | 2011-10-15 | Inst Clayton De La Rech | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen |
NZ532060A (en) | 2001-10-02 | 2005-11-25 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications |
NZ541951A (en) | 2003-03-07 | 2008-03-28 | Robarts Res Inst | Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection |
EP2055316A1 (fr) * | 2003-09-09 | 2009-05-06 | VIRxSYS Corporation | Approches basées sur un vecteur lentivirus pour la génération d'une réponse immunitaire au VIH chez les humains |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
CN101137748B (zh) | 2005-03-07 | 2011-12-14 | 罗巴斯研究机构 | 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用 |
EP3031923A1 (fr) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux |
JP2018510160A (ja) * | 2015-03-20 | 2018-04-12 | ブルーバード バイオ, インコーポレイテッド | ベクター製剤 |
WO2019009979A1 (fr) | 2017-07-06 | 2019-01-10 | The Medical College Of Wisconsin, Inc. | Nouvelle stratégie d'enrichissement in vitro et in vivo ciblant les lymphocytes dérivés de csh transduites par un vecteur pour la thérapie de troubles |
CN117467019A (zh) * | 2018-05-18 | 2024-01-30 | 郑州晟斯生物科技有限公司 | 改进的fviii融合蛋白及其应用 |
EP3854879A4 (fr) * | 2018-09-20 | 2022-06-22 | National University Corporation Tokyo Medical and Dental University | Procédé d'amélioration de la production de vecteurs de lentivirus |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031602A1 (fr) * | 1995-04-01 | 1996-10-10 | Oxford Biomedica (Uk) Limited | Vecteurs retroviraux |
US5585263A (en) * | 1994-05-20 | 1996-12-17 | University Of Alabama At Birmingham Research Foundation | Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV |
WO1997012622A1 (fr) * | 1995-10-06 | 1997-04-10 | The Salk Institute For Biological Studies | Vecteur et procede permettant d'alimenter en acide nucleique des cellules ne subissant pas de division |
WO1997020052A1 (fr) * | 1995-11-28 | 1997-06-05 | Clinical Technologies, Inc. | Vih recombine, cellules d'encapsidation modifiees et methode de traitement du syndrome d'immunodeficience acquise |
-
1998
- 1998-07-20 AU AU85762/98A patent/AU8576298A/en not_active Abandoned
- 1998-07-20 JP JP2000503232A patent/JP2001510053A/ja not_active Withdrawn
- 1998-07-20 WO PCT/US1998/014996 patent/WO1999004026A2/fr not_active Application Discontinuation
- 1998-07-20 CA CA002296319A patent/CA2296319A1/fr not_active Abandoned
- 1998-07-20 EP EP98936923A patent/EP1003894A2/fr not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585263A (en) * | 1994-05-20 | 1996-12-17 | University Of Alabama At Birmingham Research Foundation | Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV |
WO1996031602A1 (fr) * | 1995-04-01 | 1996-10-10 | Oxford Biomedica (Uk) Limited | Vecteurs retroviraux |
WO1997012622A1 (fr) * | 1995-10-06 | 1997-04-10 | The Salk Institute For Biological Studies | Vecteur et procede permettant d'alimenter en acide nucleique des cellules ne subissant pas de division |
WO1997020052A1 (fr) * | 1995-11-28 | 1997-06-05 | Clinical Technologies, Inc. | Vih recombine, cellules d'encapsidation modifiees et methode de traitement du syndrome d'immunodeficience acquise |
Non-Patent Citations (8)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107949424B (zh) * | 2015-03-20 | 2022-03-01 | 天普大学-联邦高等教育系统 | Tat诱导的基于crispr/核酸内切酶的基因编辑 |
Also Published As
Publication number | Publication date |
---|---|
EP1003894A2 (fr) | 2000-05-31 |
CA2296319A1 (fr) | 1999-01-28 |
JP2001510053A (ja) | 2001-07-31 |
WO1999004026A2 (fr) | 1999-01-28 |
AU8576298A (en) | 1999-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999004026A3 (fr) | Vecteurs lentiviraux | |
WO1995030763A3 (fr) | Vecteurs retroviraux a taux de recombinaison reduit | |
AU2998597A (en) | Crossless retroviral vectors | |
EP1285967A3 (fr) | Lignée cellulaire humaine pour l'empaquetage des rétrovirus | |
WO1998027204A3 (fr) | Genes d'encapsidation fractionnes de virus adeno-associe (aav) et lignees cellulaires comprenant ces genes utilises pour la production de vecteurs d'aav de recombinaison | |
AU4951293A (en) | Synthesis of manganese bleach catalyst | |
MX203057B (es) | Procedimiento para la sintesis electroquimica directa de fosgeno en fase gaseosa. | |
AU7545500A (en) | Producer cell for the production of retroviral vectors | |
CA2170509A1 (fr) | Adn codant le recepteur ep2 de la prostaglandine | |
CA2165954A1 (fr) | Recepteur fp de la prostaglandine et adn codant ce recepteur | |
WO2000000600A3 (fr) | Vecteurs lentiviraux | |
CA2211204A1 (fr) | Recepteur dp de prostaglandine | |
AU2997295A (en) | Composite membrane for chemical synthesis | |
AU574715B2 (en) | Non flammable aerosol propellant microemulsion | |
WO1996007739A3 (fr) | Recepteurs de type 3 de l'interleukine 1 | |
AU7361996A (en) | Composite membrane and use thereof for chemical synthesis | |
AU6139699A (en) | Packaging cell lines for hiv-derived retroviral vector particles | |
AU4766596A (en) | Ob gene product antibodies | |
WO1997008190A3 (fr) | Composes | |
AU697289B2 (en) | Photoprotective cosmetic compositions containing TIO2 nanopigments and an acylamino acid | |
AU1246399A (en) | Vectors inhibiting or delaying the binding of an immunodeficiency vi rus to cells | |
AU1504695A (en) | Synthesis gas preparation by partial oxidation-steam reforming | |
WO1995017418A3 (fr) | NOUVEAUX INTERMEDIAIRES POUR LA SYNTHESE D'AMIDES DE L-ASPARTYL-D-α-AMINOALCANOYL-(S)-N-α-ALKYLBENZYLE UTILES EN TANT QU'EDULCORANTS ARTIFICIELS | |
CA2306634A1 (fr) | Lignees de cellules d'encapsidation en suspension pour vecteurs retroviraux | |
AU5312096A (en) | Immunoassay using antibodies directed to the reaction product of enzymes used as labels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2296319 Country of ref document: CA Ref country code: CA Ref document number: 2296319 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998936923 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 85762/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1998936923 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998936923 Country of ref document: EP |